Thermo Fisher Scientific Inc. has terminated the acquisition agreement with QIAGEN, and QIAGEN will pay to Thermo Fisher an expense reimbursement payment of USD $95 million in cash in accordance with the terms of the acquisition agreement, states a Thermo Fisher Scientific press release.
Thermo Fisher announced that its offer to acquire all of the ordinary shares of QIAGEN N.V. had lapsed. Based on information provided by the settlement agents for the offer, Deutsche Bank Aktiengesellschaft and American Stock Transfer & Trust Company, QIAGEN shares, representing 47.02% of the issued and outstanding ordinary shares of QIAGEN, were validly tendered into the offer by the end of the acceptance period. Accordingly, the minimum acceptance threshold condition to the offer was not satisfied, and the offer has lapsed in accordance with its terms.
